Duoforte 27 GEL
Originaltext auf Französisch.
In Kanada zugelassenes natürliches Gesundheitsprodukt
Die Analyse oraler Dosen ist ohne einen nachgewiesenen ausschließlich oralen Verabreichungsweg nicht anwendbar.
Zusammensetzung
| Arzneilicher Inhaltsstoff und Quelle | Je Dosiseinheit laut Quelle |
|---|---|
| Acide salicylique Quelle : Synthétique | 27 % |
Nicht arzneiliche Inhaltsstoffe
Hydroxypropylcellulose, Flexible collodion, Alcool, Ethyl lactate, Méthacrylate de poly (méthyle), Polybutylene
In Kanada empfohlene Dosen
| Bevölkerungsgruppe | Alter | Menge pro Einnahme | Häufigkeit |
|---|---|---|---|
| Adultes et enfants | minimum : 3 ans | 1 Goutte(s) | 24 heures |
In Kanada zugelassene Verwendungen
For the removal of common warts.
Originaltext auf Englisch.
Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.
Warnhinweise in Kanada
Cautions and Warnings : DUOFORTE® is for external use only. DUOFORTE® is not recommended in patients with a known sensitivity or allergy to any of the ingredients. DUOFORTE® may cause eye irritation. Avoid contact with eyes and other mucous membranes. In case of accidental contact with the eyes or other mucous membranes, flush with water for 15 minutes. Avoid exposure to healthy skin. DUOFORTE® may cause skin irritation. If undue skin irritation develops, treatment should be discontinued. Consider alternative treatments if warts cover a large area of the body (more than 5 cm²) due to the potential risk of salicylate toxicity. DUOFORTE® is not recommended in patients with peripheral neuropathy except under the supervision of a physician. Oral salicylates have been associated with Reye's syndrome and hence there is a theoretical risk with topical salicylates. Therefore, use is not advised in children or teenagers during or immediately after chickenpox, influenza, or other viral infections. Patients should be advised not to inhale the vapour. It has been reported that salicylates are excreted via breast milk. Patients should be advised to consult a physician if discomfort persists. Pregnancy and Lactation Pregnancy The safety of DUOFORTE® during human pregnancy has not been established. Studies in animals given salicylic acid orally demonstrated embryo-toxicity at high doses. DUOFORTE® is not recommended during pregnancy. Lactation Salicylates are excreted in human milk. DUOFORTE® is not recommended during lactation. If used or administered during lactation, care should be taken to avoid contact with the breast area in order to avoid accidental ingestion by the infant.
Originaltext auf Englisch.
Contra-Indications : Do not use DUOFORTE® if you have diabetes or poor blood circulation. DO not use DUOFORTE® on open wounds, irritated or reddened skin or any area that is infected. Do not use DUOFORTE® on moles, birthmarks, genital warts, warts on the face or mucous membranes, warts with hair growing from them, red edges, or unusual colour.
Originaltext auf Englisch.
Known Adverse Reactions : Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency. Frequencies are defined as: rare (greater than or equal to 1/10000 to less than 1/1000). Post-marketing data Immune system disorders Rare: Application site hypersensitivity including inflammation. Skin and subcutaneous tissue disorders Rare: Application site reaction (including pain, irritation, burning sensation, erythema, and pruritus). Application site discoloration/skin discoloration. Exposure to healthy skin can lead to application site blistering and skin exfoliation. Interactions DUOFORTE® may increase the absorption of other topically applied medicines. Therefore, concomitant use of DUOFORTE® and other topical medicines on the treated area should be avoided.
Originaltext auf Englisch.
Produktdaten
- Inhaber
- Haleon US Holdings LLC
- NPN oder DIN-HM
- 01939645
- Status
- Lizenz nicht aktiv
- Lizenzdatum
- 22. Dezember 2009
- Überarbeitungsdatum
- 22. Februar 2017
- Form
- Solution semblabe au collodion.
- Verabreichungsweg
- Topique
- Art des Antrags
- DIN de transition
Quelle
Amtlicher Health-Canada-Eintrag, Zulassung 01939645
Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Originaltext auf Englisch.
Originaltext auf Französisch.
Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.
Liste in der amtlichen Überarbeitung vom (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).
Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.